Clopidogrel

Chemical formula: C₁₆H₁₆ClNO₂S  Molecular mass: 321.822 g/mol  PubChem compound: 60606

Therapeutic indications

Clopidogrel is indicated for:

Myocardial infarction

Population group: only adults (18 years old or older)

Clopidogrel is indicated in adult patients suffering from myocardial infarction (from a few days until less than 35 days).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Ischaemic stroke

Population group: only adults (18 years old or older)

Clopidogrel is indicated in adult patients suffering from ischaemic stroke (from 7 days until less than 6 months).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Peripheral arterial disease

Population group: only adults (18 years old or older)

Clopidogrel is indicated in adult patients suffering from established peripheral arterial disease.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Acute coronary syndrome

Population group: only adults (18 years old or older)

Clopidogrel is indicated in adult patients suffering from acute coronary syndrome:

  • Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA).
  • ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Prevention of atherothrombotic and thromboembolic events in atrial fibrillation

Population group: only adults (18 years old or older)

In adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with Vitamin K antagonists (VKA) and who have a low bleeding risk, clopidogrel is indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events, including stroke.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Clopidogrel is contraindicated in the following cases:

Severe hepatic impairment

Hepatic failure stage IV

Active pathological bleeding

Bleeding

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Structured Product Labeling (SPL/PLR) 2020: PLAVIX Film-coated tablet
Summary of Product Characteristics (SPC) 2018: CLOPIDOGREL ZENTIVA Film-coated tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈